Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
NCT07356375
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
DRUG:
Selexipag
Sponsor
University of Sao Paulo General Hospital